Using integrated bioinformatics analysis, CDC20 has been previously identified as a potential drug target for cholangiocarcinoma (CCA) and hepatocellular carcinoma (HCC) [60,61]. The gene discussed is CDC20; the disease is cholangiocarcinoma.